M&A Deal Summary

GlaxoSmithKline Acquires Maxinutrition Group Holdings

On December 13, 2010, GlaxoSmithKline acquired beverage company Maxinutrition Group Holdings from Darwin Private Equity for 162M GBP

Acquisition Highlights
  • This is GlaxoSmithKline’s 1st transaction in the Beverages sector.
  • This is GlaxoSmithKline’s 19th largest (disclosed) transaction.
  • This is GlaxoSmithKline’s 4th transaction in the United Kingdom.

M&A Deal Summary
Date 2010-12-13
Target Maxinutrition Group Holdings
Sector Beverages
Buyer(s) GlaxoSmithKline
Sellers(s) Darwin Private Equity
Deal Type Add-on Acquisition
Deal Value 162M GBP
Advisor(s) Hogan Lovells (Legal)

Target

Maxinutrition Group Holdings

Hemel Hempstead, United Kingdom
website
Maxinutrition is a UK company that manufactures protein-enhanced functional nutrition products. Maxinutrition, the parent company of Maximuscle, Maxifuel and Maxitone, is Europe’s leading sports nutrition company. Maximuscle is targeted at consumers who are focused on gaining muscle and increasing strength and power.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

GlaxoSmithKline

Brentford, United Kingdom

website

Category Company
Founded 1715
Sector Life Science
Employees94,066
Revenue 34.1B GBP (2020)
DESCRIPTION
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.

GlaxoSmithKline is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GlaxoSmithKline was founded in 1715 and is based in Brentford, the United Kingdom.

DEAL STATS #
Overall 20 of 31
Sector (Beverages) 1 of 1
Type (Add-on Acquisition) 14 of 23
Country (United Kingdom) 4 of 4
Year (2010) 3 of 3
Size (of disclosed) 19 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-12-06 Nanjing MeiRui Pharma

Shanghai, China

Nanjing MeiRui Pharma Co. Ltd. is a Chinese pharmaceutical business with a strong portfolio of urology and allergy products, including Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome.

Buy $70M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-03 GlaxoSmithKline - Zovirax

United Kingdom

GlaxoSmithKline - Zovirax(R) which features aciclovir as its active ingredient, is an antiviral treatment for cold sores.

Sell $300M

Seller(S) 1

SELLER

Darwin Private Equity

Guildford, United Kingdom

Investor Investor Investor Investor

website

Category Private Equity Firm
Founded 2007
PE ASSETS 217M GBP
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

Darwin Private Equity is an investment firm focused on buyout, buy-in, and turnaround investments in UK based companies. Darwin looks to hold majority positions in businesses valued between £10 and £100 million. Broad sectors of interest include consumer, industrial, media/technology, business services, and financial services. Darwin Private Equity was formed in 2007 and is based in London.

DEAL STATS #
Overall 1 of 8
Sector (Beverages) 1 of 1
Type (Add-on Acquisition) 1 of 4
Country (United Kingdom) 1 of 7
Year (2010) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-11-02 Euroffice

London, United Kingdom

Euroffice Ltd. is an online retailer of office supplies, furniture, and stationery. With an internet-only business model, Euroffice is able to supply a range of over 27,000 products at highly competitive prices with next day delivery to a customer base that is difficult to serve for the larger, integrated office supplies businesses.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-08-26 Attenda

Middlesex, United Kingdom

Attenda Ltd. is a provider of managed services and cloud platform for business critical applications.

Buy £50M
Mergr

Product

Company

Legal